Long‐Term Clinical Outcomes of Biodegradable‐ Versus Durable‐Polymer‐Coated Everolimus‐Eluting Stents in Real‐World Post‐Marketing Study
Catheterization and Cardiovascular Interventions · 2025
DOI: 10.1002/ccd.31292 ↗At a glance
Vergleichsstudie in Catheterization and Cardiovascular Interventions, 2025. Written by Waiel Abusnina and 18 co-authors. Institution: Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, District of Columbia, USA. Major MEDLINE topics: Drug-Eluting Stents, Absorbable Implants, Everolimus, Percutaneous Coronary Intervention. Cited 1 times so far (Crossref); 25 references. Funded by: Financial support was provided by the Boston Scientific Corporation., Boston Scientific Corporation.
Abstract (original language)
Background
Long‐term clinical data on biodegradable‐polymer (BP) drug‐eluting stents (DES) are limited. The objective of this study was to assess the long‐term safety and efficacy of the BP‐DES SYNERGY compared to XIENCE V, a durable‐polymer (DP)‐DES.
Methods
We compared patients treated with BP‐DES or DP‐DES at our center from 2008 to 2020. The primary outcome was major adverse cardiac events (MACE), defined as the composite of all‐cause death, Q‐wave myocardial infarction (MI), and target vessel revascularization (TVR). Secondary endpoints were all‐cause death, Q‐wave MI, target lesion revascularization (TLR), and stent thrombosis (ST).
Results
A total of 4255 patients underwent propensity‐score matching, and 380 patients from each cohort were matched. There was no significant difference between BP‐DES and DP‐DES concerning MACE (5‐year estimates: 21.6% vs. 26.6%, log‐rank p = 0.259). Furthermore, there was no difference in the TLR rate (5‐year estimates: 7.3% vs. 8.6%, log‐rank p = 0.781). All‐cause death (5‐year estimates: 13.6% vs. 12.9%, log‐rank p = 0.72) and Q‐wave MI (5‐year estimates: 0.53% vs. 1.7%, log‐rank p = 0.427) were also comparable between the two groups. Of note, the rate of very late ST was very low and similar between the groups (5‐year estimates: 0.26% vs. 0.64%, log‐rank p = 0.698).
Conclusion
BP‐DES and DP‐DES demonstrate similar safety and efficacy at 5‐year follow‐up. Both can be used for the effective treatment of coronary artery disease.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, District of Columbia, USA.
ORCID profiles: Lowell F Satler, Ron Waksman
Funding
- Financial support was provided by the Boston Scientific Corporation.
- Boston Scientific Corporation
Cite
APA
Abusnina, W., Case, B. C., Zhang, C., Chitturi, K. R., Sawant, V., Chaturvedi, A., Haberman, D., Lupu, L., Sutton, J. A., Ali, S. W., Deksissa, T., Pokharel, S., Ozturk, S. T., Margulies, A., Ben-Dor, I., Hashim, H. D., Satler, L. F., Garcia-Garcia, H. M., & Waksman, R. (2025). Long‐Term Clinical Outcomes of Biodegradable‐ Versus Durable‐Polymer‐Coated Everolimus‐Eluting Stents in Real‐World Post‐Marketing Study. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.31292
Vancouver
Abusnina W, Case BC, Zhang C, Chitturi KR, Sawant V, Chaturvedi A, et al. Long‐Term Clinical Outcomes of Biodegradable‐ Versus Durable‐Polymer‐Coated Everolimus‐Eluting Stents in Real‐World Post‐Marketing Study. Catheterization and Cardiovascular Interventions. 2025. doi:10.1002/ccd.31292
BibTeX
@article{Abusnina2025,
author = {Abusnina, Waiel and Case, Brian C and Zhang, Cheng and Chitturi, Kalyan R and Sawant, Vaishnavi and Chaturvedi, Abhishek and Haberman, Dan and Lupu, Lior and Sutton, Jospeh A and Ali, Syed W and Deksissa, Teshome and Pokharel, Shreejana and Ozturk, Sevket T and Margulies, Adrian and Ben-Dor, Itsik and Hashim, Hayder D and Satler, Lowell F and Garcia-Garcia, Hector M and Waksman, Ron},
title = {Long‐Term Clinical Outcomes of Biodegradable‐ Versus Durable‐Polymer‐Coated Everolimus‐Eluting Stents in Real‐World Post‐Marketing Study},
journal = {Catheterization and Cardiovascular Interventions},
year = {2025},
doi = {10.1002/ccd.31292}
}
EUVIMED